Shen Hengyan, Bai Xinyu, Liu Jie, Liu Ping, Zhang Tao
Department of Laboratory Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China.
Front Oncol. 2022 Oct 10;12:1001400. doi: 10.3389/fonc.2022.1001400. eCollection 2022.
Cholangiocarcinoma (CCA) is a rare malignant tumor associated with poor prognosis. This study aimed to identify CCA biomarkers by investigating differentially expressed genes (DEGs) between CCA patients and healthy subjects obtained from the Gene Expression Omnibus database. Bioinformatics tools, including the Illumina BaseSpace Correlation Engine (BSCE) and Gene Expression Profiling Interactive Analysis (GEPIA), were used. The initial DEGs from GSE26566, GSE31370, and GSE77984 were analyzed using GEO2R and Venn, and protein-protein interaction networks were constructed using STRING. The BSCE was applied to assess curated CCA studies to select additional DEGs and them DEGs across the 10 biosets, which was supported by findings in the literature. The final 18 DEGs with clinical significance for CCA were further verified using GEPIA. These included , , , , , , , , and , which were upregulated, and , , , , , , , , and , which were downregulated in CCA patients. Among these 18 genes, 56 groups of genes (two in each group) were significantly related, and none were independently and differentially expressed. The hub genes , , , and , which were most correlated with the 18 DEGs, were screened using STRING. The significantly low expression of , , and and significantly high expression of were verified by immunohistochemical analysis. Overall, four CCA biomarkers were identified that might regulate the occurrence and development of this disease and affect the patient survival rate, and they have the potential to become diagnostic and therapeutic targets for patients with CCA.
胆管癌(CCA)是一种预后较差的罕见恶性肿瘤。本研究旨在通过调查从基因表达综合数据库中获取的CCA患者与健康受试者之间的差异表达基因(DEG)来鉴定CCA生物标志物。使用了包括Illumina BaseSpace关联引擎(BSCE)和基因表达谱交互式分析(GEPIA)在内的生物信息学工具。使用GEO2R和Venn分析来自GSE26566、GSE31370和GSE77984的初始DEG,并使用STRING构建蛋白质-蛋白质相互作用网络。应用BSCE评估经过整理的CCA研究,以选择额外的DEG以及10个生物集之间的DEG,这得到了文献研究结果的支持。使用GEPIA进一步验证了对CCA具有临床意义的最终18个DEG。这些基因包括在CCA患者中上调的[具体基因1]、[具体基因2]、[具体基因3]、[具体基因4]、[具体基因5]、[具体基因6]、[具体基因7]、[具体基因8]和[具体基因9],以及下调的[具体基因10]、[具体基因11]、[具体基因12]、[具体基因13]、[具体基因14]、[具体基因15]、[具体基因16]、[具体基因17]和[具体基因18]。在这18个基因中,56组基因(每组两个)显著相关,且无独立差异表达。使用STRING筛选出与这18个DEG相关性最高的枢纽基因[枢纽基因1]、[枢纽基因2]、[枢纽基因3]和[枢纽基因4]。通过免疫组织化学分析验证了[具体基因19]、[具体基因20]和[具体基因21]的显著低表达以及[具体基因22]的显著高表达。总体而言,鉴定出了四种CCA生物标志物,它们可能调节该疾病的发生和发展并影响患者生存率,并且有潜力成为CCA患者的诊断和治疗靶点。